ProfileGDS5678 / 1452072_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 79% 79% 78% 75% 77% 76% 66% 74% 73% 80% 83% 80% 81% 82% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.5343279
GSM967853U87-EV human glioblastoma xenograft - Control 25.4883579
GSM967854U87-EV human glioblastoma xenograft - Control 35.4135378
GSM967855U87-EV human glioblastoma xenograft - Control 45.1237575
GSM967856U87-EV human glioblastoma xenograft - Control 55.2057677
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.990376
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.0069666
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.8713474
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.775173
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.6635180
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.0291583
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.6531880
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.8459281
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.8507882